Search

everythinglearnresearchcommunity

for

Search:↓

A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

The user is using 0.5mg dutasteride daily and 3mg oral minoxidil daily for hair loss, but hasn't seen improvements after five months. They report miniaturization and thinning, especially at the hairline and crown, and are advised to wait at least a year for better results.

The conversation discusses a prescription for hair loss treatment. Minoxidil is mentioned as a treatment that should be used daily, not just two days a week.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.

The user has been using a treatment of 0.1% topical finasteride, 5% minoxidil, dermastamping, and vitamin D3 supplements for 85 days and is seeing good progress. Other users note the effectiveness of topical finasteride despite it being less potent.

A 22-year-old male has been using Dutasteride 0.5 mg every other day and Minoxidil 5% daily since December 2024 for hair loss, with no side effects reported. Users discuss varying dosages of Dutasteride, with some expressing concerns about higher doses.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.

A 20-year-old is experiencing hair thinning and is considering Clascoterone and Minoxidil as treatments, avoiding finasteride due to concerns about fertility and hormones. A suggestion was made to use Clascoterone for local DHT targeting and combine it with Minoxidil for maintenance and regrowth while avoiding systemic side effects.

A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.

The conversation discusses hair loss treatments, specifically topical dutasteride, minoxidil, and finasteride. Users share experiences and opinions on the effectiveness and side effects of these treatments.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

The user is managing hair loss with oral finasteride, recently switching to dutasteride, and topical minoxidil, but faces challenges due to seborrheic dermatitis. They seek advice on effective regrowth methods that don't worsen their condition, with suggestions including various shampoos like Vichy Dercos and ketoconazole.

A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.

A 21-year-old male is using a topical treatment for hair loss, including Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and Hydrocortisone, along with derma rolling. He reports no side effects from the treatment and seeks feedback on its effectiveness for hair regrowth.

A user is seeking advice on using a DIY solution of topical finasteride (Fynzur 2.275mg/ml) mixed with minoxidil for hair loss. They are concerned about achieving full scalp coverage and prefer using a scalp applicator over a spray.

The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The user experienced side effects like shallow breathing, loss of libido, and erectile issues after using topical finasteride with minoxidil for hair loss. They are considering whether to continue the treatment despite these side effects.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

The conversation discusses the use of dutasteride for hair regrowth, with the user planning to add topical minoxidil. The user reports improved hair strand quality and beard growth with dutasteride, while noting some side effects compared to finasteride.

User shared positive results after 4 months using 1.25mg finasteride, topical minoxidil, daily biotin, and weekly dermarolling. They expressed gratitude to another user for the advice.

OP used finasteride 1mg and 2.5mg oral minoxidil since late April, showing hair improvement despite some initial libido issues. Users discussed side effects, costs, and alternative treatments, with OP noting increased facial hair but no significant body hair growth.

The user is using finasteride 1mg every other day and seeks a topical solution to complement it, excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.